Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer

被引：5
|
作者：
McNamara, Blair [1 ]
Chang, Yifan [1 ]
Mutlu, Levent [1 ]
Harold, Justin [1 ]
Santin, Alessandro D. [1 ]
机构：
[1] Yale Univ, Dept Obstet Gynecol & Reprod Sci, Sch Med, 333 Cedar St,LSOG 305,POB 208063, New Haven, CT 06520 USA
来源：
EXPERT OPINION ON BIOLOGICAL THERAPY | 2023年 / 23卷 / 03期
关键词：
Cervical cancer; immune checkpoint inhibitor; PD-1; pembrolizumab; bevacizumab; HUMAN-PAPILLOMAVIRUS; MONOCLONAL-ANTIBODY; INTRAEPITHELIAL NEOPLASIA; EXPRESSION; EFFICACY; SAFETY; WOMEN; ANGIOGENESIS; STIMULATION; STATISTICS;
D O I：
10.1080/14712598.2023.2182679
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
IntroductionDespite progress on prevention and treatment of cervical cancer, global morbidity and mortality remain high. Immunotherapy, in conjunction with standard chemotherapy, presents an opportunity for further benefit.Areas coveredHere we report the pharmacologic properties, evidence for clinical efficacy, safety, and tolerability of pembrolizumab in addition to standard chemotherapy with and without bevacizumab for treatment of advanced or recurrent cervical cancer.Expert opinionIn patients with progressive, recurrent, or metastatic PD-L1 expressing cervical cancer, without contraindication to anti-VEGF therapy, the use of pembrolizumab with bevacizumab and standard chemotherapy with carboplatin and paclitaxel is warranted. There is no evidence to support the use of pembrolizumab for this population broadly, and no evidence to support its use in PD-L1 non-expressing tumors.
引用
收藏
页码：227 / 233
页数：7
相关论文
共 50 条
  • [31] Cost-effectiveness analysis of pembrolizumab plus chemotherapy for patients with recurrent or metastatic cervical cancer in China
    Zheng, Zhiwei
    Song, Xiaobing
    Qiu, Guodong
    Xu, Siqi
    Cai, Hongfu
    CURRENT MEDICAL RESEARCH AND OPINION, 2023, 39 (03) : 433 - 440
  • [32] Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo- controlled, phase 3 trial
    Monk, Bradley J.
    Tewari, Krishnansu S.
    Dubot, Coraline
    Caceres, M. Valeria
    Hasegawa, Kosei
    Shapira-Frommer, Ronnie
    Salman, Pamela
    Yanez, Eduardo
    Guemues, Mahmut
    Mendoza, Mivael Olivera Hurtado de
    Samouelian, Vanessa
    Castonguay, Vincent
    Arkhipov, Alexander
    Tekin, Cumhur
    Li, Kan
    Nguyen, Allison Martin
    Monberg, Matthew J.
    Colombo, Nicoletta
    Lorusso, Domenica
    LANCET ONCOLOGY, 2023, 24 (04): : 392 - 402
  • [33] EFFICACY AND SAFETY OF BEVACIZUMAB COMBINATION CHEMOTHERAPY FOR RECURRENT CERVICAL CANCER
    Kusakabe, M.
    Tanikawa, M.
    Oda, K.
    Nagasaka, K.
    Miyamoto, Y.
    Sone, K.
    Mori, M.
    Tsuruga, T.
    Matsumoto, Y.
    Osuga, Y.
    Fujii, T.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 318 - 318
  • [34] COST EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB AS FIRST-LINE TREATMENT FOR PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER IN GREECE
    Yfantopoulos, N.
    Gountas, I
    Swami, S.
    Skroumpelos, A.
    Karokis, A.
    VALUE IN HEALTH, 2023, 26 (12) : S62 - S62
  • [35] A COMPARISON OF ADVERSE OUTCOMES WITH THE USE OF BEVACIZUMAB WITH CISPLATIN/PACLITAXEL OR CARBOPLATIN/PACLITAXEL IN RECURRENT, PERSISTENT OR METASTATIC CERVICAL CANCER
    Kotait, Maryam
    Anzai, Tessa
    Chow, Rosa
    Reade, Clare
    Carlson, Vanessa
    Eiriksson, Lua
    Jimenez, Waldo
    Nguyen, Julie
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A75 - A76
  • [36] First-Line Pembrolizumab plus Chemotherapy Versus Placebo plus Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826
    Monk, Bradley J.
    Colombo, Nicoletta
    Tewari, Krishnansu S.
    Dubot, Coraline
    Caceres, M. Valeria
    Hasegawa, Kosei
    Shapira-Frommer, Ronnie
    Salman, Pamela
    Yanez, Eduardo
    Gumus, Mahmut
    de Mendoza, Mivael Olivera Hurtado
    Samouelian, Vanessa
    Castonguay, Vincent
    Arkhipov, Alexander
    Tekin, Cumhur
    Li, Kan
    Keefe, Stephen M.
    Lorusso, Domenica
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (36) : 5505 - +
  • [37] Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase III KEYNOTE-826 study
    Colombo, N.
    Dubot, C.
    Lorusso, D.
    Caceres, V.
    Hasegawa, K.
    Shapira-Frommer, R.
    Tewari, K. S.
    Salman, P.
    Hoyos, E.
    Yanez, E.
    Gumus, M.
    De Mendoza, M. Olivera Hurtado
    Samouelian, V.
    Castonguay, V.
    Arkhipov, A.
    Toker, S.
    Li, K.
    Keefe, S. M.
    Monk, B. J.
    ANNALS OF ONCOLOGY, 2021, 32 : S1307 - S1308
  • [38] The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study
    Zhu, Jianqing
    Pan, Mei
    Yu, Hao
    Chao, Hongtu
    Chen, Youguo
    Zhao, Hongqin
    Niu, Shuhuai
    Gao, Yuhua
    Wen, Qiang
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [39] First-Line Treatment With Atezolizumab Plus Bevacizumab and Chemotherapy for US Patients With Metastatic, Persistent, or Recurrent Cervical Cancer: A Cost-Effectiveness Analysis
    Lei, Jianying
    Zhang, Jiahao
    You, Caicong
    Liu, Maobai
    Li, Na
    VALUE IN HEALTH, 2024, 27 (11) : 1528 - 1534
  • [40] Improving survival from metastatic, recurrent, or persistent cervical cancer
    Mileshkin, Linda R.
    Manoharan, Sathya
    LANCET, 2024, 403 (10421): : 2 - 4
12345